Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

Trilaciclib is an intravenous CDK4/6 inhibitor administered prior to chemotherapy to preserve haematopoietic stem and progenitor cells and immune system function from chemotherapy‐induced damage (myelopreservation). The effects of administering trilaciclib prior to carboplatin, etoposide and atezoli...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Int J Cancer
Autores principales: Daniel, Davey, Kuchava, Vladimer, Bondarenko, Igor, Ivashchuk, Oleksandr, Reddy, Sreekanth, Jaal, Jana, Kudaba, Iveta, Hart, Lowell, Matitashvili, Amiran, Pritchett, Yili, Morris, Shannon R., Sorrentino, Jessica A., Antal, Joyce M., Goldschmidt, Jerome
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8048941/
https://ncbi.nlm.nih.gov/pubmed/33348420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33453
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares